Xiaowei Xue | Environmental Epidemiology | Innovative Research Award

Published on by Cardiology and Cardiovascular Medicine

Innovative Research Award

Xiaowei Xue
Fudan University, China
Xiaowei Xue
Affiliation Fudan University
Country China
Scopus ID 57314141000
Documents 24
Citations 742
h-index 12
Subject Area Environmental Epidemiology
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID 0009-0009-3761-1773

Xiaowei Xue is a researcher at Fudan University whose work lies at the intersection of environmental epidemiology and cardiovascular health. Through large-scale population studies, longitudinal monitoring, and exposure assessment research, the researcher has examined how air pollution, temperature variability, and environmental risk factors influence cardiovascular outcomes. The scholarly record reflects a sustained focus on hypertension, arterial stiffness, heart rate variability, and preventive public health strategies, contributing valuable evidence to contemporary cardiovascular and environmental health research.[1]

Abstract

The research portfolio of Xiaowei Xue focuses on understanding environmental determinants of cardiovascular disease and population health. Recent investigations have examined associations between air pollution exposure, blood pressure regulation, arterial stiffness, heart rate variability, and mortality from hypertension-related complications. By combining epidemiological methods with advanced exposure assessment techniques, the researcher has contributed evidence supporting preventive approaches to cardiovascular risk reduction and environmental health policy development.[2]

Keywords

  • Environmental Epidemiology
  • Hypertension
  • Air Pollution
  • Cardiovascular Health
  • Arterial Stiffness
  • Public Health Research

Introduction

Environmental exposures are increasingly recognized as important contributors to cardiovascular morbidity and mortality. Research addressing pollution, climate-related variables, and physiological responses provides valuable insights into disease prevention. Xiaowei Xue has contributed to this field through studies evaluating the cardiovascular effects of particulate matter, temperature fluctuations, and air purification interventions in diverse populations.[3]

Research Profile

The researcher has accumulated 742 citations and an h-index of 12, demonstrating notable scholarly influence within environmental epidemiology and cardiovascular research.[1] Publications appear in leading journals including the Journal of the American College of Cardiology, Environmental Pollution, and Environmental Science & Technology. The research profile highlights expertise in population-level cardiovascular risk assessment and environmental exposure science.

Research Contributions

A major contribution includes a case-crossover study involving approximately 2.1 million deaths in China, which investigated short-term air pollution exposure and mortality from hypertension and associated multiorgan complications.[2] Additional studies explored how fine particulate matter may influence arterial stiffness through inflammatory pathways and how outdoor temperature affects ambulatory blood pressure patterns.[3] The researcher has also examined cardiovascular benefits of air purification among children through randomized clinical investigation and evaluated temperature-related effects on heart rate variability using longitudinal panel data. These studies contribute to understanding environmental interventions capable of supporting cardiovascular health protection.[4]

Publications

  1. Short-Term Exposure to Air Pollution Increases Mortality From Hypertension and its Multiorgan Complications. DOI
  2. Short-term Exposure to Fine Particulate Matter and Arterial Stiffness. DOI
  3. Cardiovascular Benefits of Air Purification in Children. DOI

Research Impact

The impact of Xiaowei Xue’s research extends across cardiovascular epidemiology, environmental medicine, and public health. Findings have strengthened understanding of how environmental exposures contribute to cardiovascular risk and have provided evidence relevant to health policy, pollution control strategies, and preventive medicine initiatives.[5]

Award Suitability

Xiaowei Xue demonstrates strong suitability for the Innovative Research Award through impactful investigations connecting environmental exposures with cardiovascular outcomes. The combination of high citation performance, interdisciplinary methodology, and contributions to population health research aligns closely with the objectives of the International Research Awards on Cardiology & Cardiovascular Medicine.[1]

Conclusion

Through investigations of air pollution, temperature exposure, blood pressure regulation, and cardiovascular prevention strategies, Xiaowei Xue has contributed meaningful evidence to environmental epidemiology and cardiovascular medicine. The researcher’s work supports a broader understanding of environmental determinants of health and their implications for disease prevention and public health advancement.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Xiaowei Xue, Author ID 57314141000. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57314141000
  2. Xue, X., et al. (2026). Short-Term Exposure to Air Pollution Increases Mortality From Hypertension and its Multiorgan Complications.
    https://doi.org/10.1016/j.jacc.2026.01.006
  3. He, X., et al. (2026). Short-term Exposure to Fine Particulate Matter and its Chemical Constituents May Affect Arterial Stiffness.
    https://doi.org/10.1016/j.envpol.2026.127735
  4. Xue, X., et al. (2025). Cardiovascular Benefits of Air Purification in Children.
    https://doi.org/10.1021/acs.est.5c06712
  5. Hu, J., et al. (2025). Attending to the Effects of Outdoor Temperature on Blood Pressure.
    https://doi.org/10.1016/j.envpol.2025.126301

Isa Ardahanli | Hypertension | Research Excellence Award

Published on by Cardiology and Cardiovascular Medicine

Research Excellence Award

Isa Ardahanli
Bilecik Şeyh Edebali University, Turkey
Isa Ardahanli
Affiliation Bilecik Şeyh Edebali University
Country Turkey
Scopus ID 56520257000
Documents 35
Citations 144
h-index 7
Subject Area Hypertension
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID
0000-0002-9309-803X

Isa Ardahanli is a researcher affiliated with Bilecik Şeyh Edebali University whose academic work focuses on hypertension, cardiovascular medicine, pharmacological interactions, and translational clinical research. The researcher has contributed to publications addressing aortic stiffness, antiplatelet therapy, heart failure management, and cardiovascular complications associated with pharmacological interventions. The scholarly profile demonstrates interdisciplinary engagement in cardiovascular sciences and clinical medicine with growing citation impact in peer-reviewed research.[1]

Abstract

The research activities of Isa Ardahanli involve cardiovascular medicine, hypertension management, pharmacological safety, and diagnostic assessment methodologies. Published studies and commentaries have explored aortic stiffness in subclinical hypothyroidism, dual antiplatelet therapy in coronary artery disease, and comparative therapeutic strategies in heart failure management. The researcher has also contributed to interdisciplinary investigations integrating artificial intelligence and spectrochemical analysis for critically ill patient assessment. These contributions reflect ongoing involvement in clinically relevant cardiovascular and translational research.[2]

Keywords

  • Hypertension
  • Cardiovascular Medicine
  • Heart Failure
  • Aortic Stiffness
  • Clinical Pharmacology
  • Artificial Intelligence in Medicine

Introduction

Cardiovascular research continues to emphasize the importance of diagnostic precision, pharmacological safety, and evidence-based therapeutic strategies. Studies addressing hypertension, antiplatelet therapy, and heart failure management are central to improving patient outcomes and reducing cardiovascular risk. Isa Ardahanli has contributed to these research areas through scholarly commentaries, collaborative investigations, and publications focused on cardiovascular pharmacology and clinical assessment techniques.[3]

Research Profile

According to available Scopus metrics, Isa Ardahanli has achieved 144 citations and an h-index of 7, indicating recognized scholarly engagement within cardiovascular medicine and hypertension research.[1] The publication record includes contributions to journals such as Acta Cardiologica, Talanta, and Arquivos Brasileiros de Cardiologia. Research themes include cardiovascular therapeutics, diagnostic methods, and interdisciplinary medical technologies.

Research Contributions

A notable contribution involves commentary on non-invasive oscillometric approaches for evaluating aortic stiffness in patients with subclinical hypothyroidism. This work discusses diagnostic methodologies relevant to cardiovascular risk stratification and vascular assessment.[2] The researcher has also participated in studies examining dual antiplatelet therapy among Turkish patients with coronary artery disease and analyses of therapeutic strategies in heart failure management. Additional interdisciplinary work integrated explainable artificial intelligence and spectrochemical methods to evaluate critically ill patients with COVID-19, demonstrating broader translational research engagement.[4]

Publications

  1. Commentary on the Role of Non-invasive Oscillometric Methods in Assessing Aortic Stiffness.
    DOI Link
  2. Fixed-Dose Antiplatelet Dual Combination in Patients with Coronary Artery Disease.
    DOI Link
  3. Spectrochemical and Explainable Artificial Intelligence Approaches for Critically Ill Patients with COVID-19.
    DOI Link

Research Impact

The researcher’s publications contribute to discussions concerning cardiovascular risk management, therapeutic optimization, and innovative diagnostic methodologies. Collaborative studies addressing hypertension and cardiovascular pharmacology support evidence-based clinical practice and ongoing advancements in cardiovascular medicine.[5]

Award Suitability

Isa Ardahanli demonstrates suitability for the Research Excellence Award through contributions to hypertension research, cardiovascular therapeutics, and interdisciplinary clinical investigations. The publication record, citation performance, and engagement in cardiovascular-focused studies align with the objectives of the International Research Awards on Cardiology & Cardiovascular Medicine.[3]

Conclusion

Isa Ardahanli has contributed to cardiovascular medicine through research involving hypertension, vascular assessment, pharmacological evaluation, and translational healthcare technologies. The researcher’s interdisciplinary publications provide clinically relevant insights that support diagnostic innovation and evidence-based cardiovascular practice within contemporary medical research.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Isa Ardahanli, Author ID 56520257000. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56520257000
  2. Aslan, R., et al. (2026). Commentary on the Role of Non-invasive Oscillometric Methods in Assessing Aortic Stiffness in Subclinical Hypothyroidism.
    https://doi.org/10.1080/00015385.2025.2453800
  3. Aslan, R., et al. (2025). Comparative Effectiveness of Torsemide and Furosemide in Heart Failure.
    https://doi.org/10.1080/00015385.2025.2476890
  4. Tokgoz, G., et al. (2024). Spectrochemical and Explainable Artificial Intelligence Approaches for Molecular Identification in Critically Ill Patients.
    https://doi.org/10.1016/j.talanta.2024.126652
  5. Oz, A., et al. (2024). Fixed-Dose Antiplatelet Dual Combination in Patients with Coronary Artery Disease in Turkish Population.
    https://doi.org/10.36660/ABC.20240202I

Gabriele d’Ettorre | Epidemiology | Innovative Research Award

Published on by Cardiology and Cardiovascular Medicine

Innovative Research Award

Gabriele d’Ettorre
Local Health Authority of Lecce, Italy
Gabriele d’Ettorre
Affiliation Local Health Authority of Lecce
Country Italy
Scopus ID 58781724100
Documents 44
Citations 965
h-index 15
Subject Area Epidemiology
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID 0000-0001-8714-1612

Gabriele d’Ettorre is an Italian researcher affiliated with the Local Health Authority of Lecce whose work focuses on epidemiology, occupational health, public health resilience, and cardiovascular risk assessment. The researcher has contributed to studies examining workplace-related cardiovascular risks, environmental exposure, infectious disease preparedness, and healthcare worker wellbeing. The scholarly profile reflects interdisciplinary engagement in public health and preventive medicine with applications relevant to cardiovascular medicine and occupational epidemiology.[1]

Abstract

The research contributions of Gabriele d’Ettorre focus on epidemiology, occupational medicine, and public health studies relevant to cardiovascular risk prevention and healthcare resilience. Published investigations include analyses of cardiovascular risk among shift-working healthcare professionals, environmental exposure-related disease risks, and occupational health concerns in clinical settings. The researcher’s interdisciplinary approach combines epidemiological methods with public health policy perspectives to address emerging healthcare challenges and preventive medicine strategies.[2]

Keywords

  • Epidemiology
  • Occupational Health
  • Cardiovascular Risk
  • Public Health
  • Healthcare Workers
  • Preventive Medicine

Introduction

Epidemiological research plays a significant role in understanding occupational and environmental determinants of cardiovascular disease and public health outcomes. Studies involving healthcare workers, migrant populations, and environmental exposures provide important evidence for preventive healthcare strategies and occupational safety policies. Gabriele d’Ettorre has contributed to this field through investigations examining workplace health risks, resilience during respiratory epidemics, and modifiable cardiovascular risk factors among healthcare professionals.[3]

Research Profile

According to available Scopus metrics, Gabriele d’Ettorre has accumulated 965 citations and an h-index of 15, indicating substantial scholarly visibility in epidemiology and public health research.[1] The researcher has authored and co-authored studies published in peer-reviewed journals including the Journal of Clinical Medicine, International Journal of Dermatology, and British Journal of Cancer. The publication portfolio reflects interdisciplinary engagement across occupational medicine, epidemiology, and healthcare policy research.

Research Contributions

Among the researcher’s notable studies is a gender-stratified cross-sectional investigation evaluating cardiovascular risk and modifiable risk factors among shift-working healthcare workers. This work contributes to understanding occupational determinants associated with cardiovascular health and workplace-related stress exposure.[2] Additional contributions include research addressing migrant health, environmental arsenic exposure, and occupational headache disorders among female nurses.[4]

Publications

  1. Cardiovascular Risk and Modifiable Risk Factors in Shift-Working Healthcare Workers. DOI: 10.3390/jcm15114028
  2. Skin Health for All, Revisited: Beyond Infections, Toxic and Occupational Exposures as Hidden Determinants of Migrant Dermatoses. DOI:
    10.1111/ijd.70411
  3. Arsenic Exposure and Cancer Risk Among Migrant Populations. DOI: 10.1038/s41416-026-03424-y

Research Impact

The researcher’s work contributes to occupational health policy discussions and preventive medicine strategies relevant to cardiovascular and public health systems. Investigations concerning healthcare worker wellbeing and environmental exposure support evidence-based approaches for reducing occupational risk factors and improving population health outcomes.[5]

Award Suitability

Gabriele d’Ettorre demonstrates suitability for recognition within the International Research Awards on Cardiology & Cardiovascular Medicine due to contributions involving cardiovascular risk assessment, occupational epidemiology, and healthcare resilience research. The publication profile and citation impact reflect sustained scholarly engagement in clinically relevant public health investigations.[2]

Conclusion

Gabriele d’Ettorre has contributed to epidemiology and occupational health research through studies addressing cardiovascular risk, healthcare worker wellbeing, and public health resilience. The researcher’s interdisciplinary investigations provide relevant insights into preventive healthcare and occupational safety, supporting broader understanding of modifiable risk factors within public health and cardiovascular medicine.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Gabriele d’Ettorre, Author ID 58781724100. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=58781724100
  2. d’Ettorre, G., et al. (2026). Cardiovascular Risk and Modifiable Risk Factors in Shift-Working Healthcare Workers. Journal of Clinical Medicine.
    https://doi.org/10.3390/jcm15114028
  3. Ceccarelli, G., et al. (2026). Skin Health for All, Revisited. International Journal of Dermatology.
    https://doi.org/10.1111/ijd.70411
  4. Ceccarelli, G., et al. (2026). Arsenic Exposure and Cancer Risk Among Migrant Populations. British Journal of Cancer.
    https://doi.org/10.1038/s41416-026-03424-y
  5. D’Ettorre, G., et al. (2025). Occupational Risk for Headache Disorders in Female Registered Nurses. La Medicina del lavoro.
    https://doi.org/10.23749/mdl.v116i6.17715

Kun Bu | Cardiovascular Pharmacology | Innovative Research Award

Published on by Cardiology and Cardiovascular Medicine

Innovative Research Award

Kun Bu
University of South Florida, United States
Kun Bu
Affiliation University of South Florida
Country United States
Scopus ID 57223366298
Documents 10
Citations 68
h-index 6
Subject Area Cardiovascular Pharmacology
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID
0009-0006-9526-3023

Kun Bu is a researcher affiliated with the University of South Florida whose scholarly contributions focus on cardiovascular pharmacology, adverse drug event analysis, transcriptomic profiling, and computational biomedical research. The researcher has participated in multidisciplinary studies examining cardiovascular safety, pharmacovigilance, and molecular mechanisms associated with therapeutic interventions. Through publications indexed in Scopus and peer-reviewed scientific journals, the researcher has contributed to investigations involving electronic health records, FDA adverse event reporting data, and transcriptomic methodologies relevant to cardiovascular medicine and drug safety evaluation.[1]

Abstract

The research activities of Kun Bu are centered on cardiovascular pharmacology, pharmacovigilance, and bioinformatics-driven approaches for evaluating therapeutic safety and adverse cardiovascular outcomes. The researcher has contributed to studies integrating FDA Adverse Event Reporting System (FAERS) data, electronic health records, and transcriptomic analyses to investigate drug-associated cardiovascular risks and molecular mechanisms. These investigations support evidence-based evaluation of therapeutic safety and contribute to broader understanding of adverse cardiovascular reactions associated with clinical pharmacotherapy.[2]

Keywords

  • Cardiovascular Pharmacology
  • Pharmacovigilance
  • FAERS Analysis
  • Transcriptomics
  • Drug Safety
  • Electronic Health Records
  • Cardiovascular Risk Assessment
  • Biomedical Data Science

Introduction

Cardiovascular pharmacology is an evolving scientific discipline that combines molecular biology, clinical medicine, and computational analysis to evaluate therapeutic efficacy and drug-related adverse effects. Modern pharmacovigilance research increasingly incorporates large-scale biomedical databases and transcriptomic profiling to identify molecular pathways associated with cardiovascular complications and treatment outcomes.[3] Kun Bu has contributed to this interdisciplinary field through collaborative investigations involving adverse event reporting systems, transcriptomic analysis, and integrated biomedical data interpretation. The researcher’s work addresses clinically relevant questions associated with cardiovascular safety, adverse drug reactions, and translational pharmacological research within cardiovascular medicine.[1]

Research Profile

Kun Bu is affiliated with the University of South Florida and has developed an academic profile focused on cardiovascular pharmacology and computational biomedical research. According to available Scopus metrics, the researcher has accumulated 68 citations with an h-index of 6, reflecting scholarly visibility and research engagement within the scientific literature.[1] The publication portfolio includes peer-reviewed journal articles in journals such as Pharmaceuticals and Genes, with studies addressing cardiovascular risks associated with COVID-19 therapeutics, dexmedetomidine-associated bradycardia, and statin-associated rhabdomyolysis. These contributions emphasize integration of pharmacological data analytics and molecular profiling techniques.[2]

Research Contributions

One of the researcher’s notable contributions involves integrated analysis of cardiovascular risks associated with COVID-19 therapeutics using FAERS data, electronic health records, and transcriptomics. This work explores potential adverse cardiovascular effects linked to therapeutic interventions and contributes to improved pharmacovigilance methodologies.[2] Additional research examined the association between dexmedetomidine and bradycardia through combined analysis of adverse event reporting systems and transcriptomic profiles. The study contributes to understanding molecular mechanisms and clinical patterns associated with cardiovascular adverse reactions.[3] The researcher has also contributed to investigations regarding statin-associated rhabdomyolysis using transcriptomic and FAERS-based methodologies. Such studies support ongoing evaluation of therapeutic safety and risk stratification within cardiovascular pharmacology and clinical medicine.[4]

Publications

  1. Cardiovascular Risks of COVID-19 Therapeutics: Integrated Analysis of FAERS, Electronic Health Records, and Transcriptomics. Pharmaceuticals (2026). DOI: 10.3390/ph19040574
  2. The Association Between Dexmedetomidine and Bradycardia: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles. Genes (2025). DOI: 10.3390/genes16060615
  3. The Association Between Statin Drugs and Rhabdomyolysis: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles. Genes (2025). DOI: 10.3390/genes16030248

Research Impact

The scholarly contributions of Kun Bu support the advancement of cardiovascular pharmacology and translational biomedical research. By integrating transcriptomics, adverse event databases, and electronic health records, the researcher’s studies contribute to improved understanding of cardiovascular safety profiles and drug-associated adverse reactions.[2] The citation profile and interdisciplinary publication record demonstrate measurable academic engagement within pharmacology and cardiovascular medicine. The research output contributes to contemporary discussions concerning therapeutic safety assessment and computational approaches in biomedical science.[1]

Award Suitability

Kun Bu’s research profile demonstrates relevance to the International Research Awards on Cardiology & Cardiovascular Medicine through contributions to cardiovascular pharmacology and pharmacovigilance research. The researcher’s investigations address clinically important issues involving drug safety, adverse cardiovascular outcomes, and molecular risk assessment.[3] The combination of peer-reviewed publications, citation metrics, and interdisciplinary scientific methodologies supports recognition within the field of cardiovascular medicine. The researcher’s contributions align with ongoing efforts to improve evidence-based therapeutic evaluation and cardiovascular risk analysis.[4]

Conclusion

Kun Bu has contributed to the interdisciplinary field of cardiovascular pharmacology through research focused on adverse drug event analysis, transcriptomic profiling, and integrated biomedical data interpretation. The researcher’s publication record demonstrates engagement in clinically relevant investigations involving cardiovascular risk assessment and pharmacovigilance. These scholarly contributions support ongoing advancement in cardiovascular medicine and evidence-based therapeutic safety evaluation.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Kun Bu, Author ID 57223366298. Scopus. https://www.scopus.com/authid/detail.uri?authorId=57223366298
  2. Zhu, X., Kuppa, S. A., Umeukeje, G., Morris, R., Bui, L., Bu, K., Zhang, J., Wei, J., & Cheng, F. (2026). Cardiovascular Risks of COVID-19 Therapeutics: Integrated Analysis of FAERS, Electronic Health Records, and Transcriptomics. Pharmaceuticals. DOI: https://doi.org/10.3390/ph19040574
  3. Morris, R., Kuppa, S. A., Zhu, X., Bu, K., Han, W., & Cheng, F. (2025). The Association Between Dexmedetomidine and Bradycardia: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles. Genes. DOI: https://doi.org/10.3390/genes16060615
  4. Morris, R., Bu, K., Han, W., Wood, S., Hernandez Velez, P. M., Ward, J., Crescitelli, A., Martin, M., & Cheng, F. (2025). The Association Between Statin Drugs and Rhabdomyolysis: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles. Genes.
    DOI: https://doi.org/10.3390/genes16030248

Michael Keller | Cardiac Surgery | Innovative Research Award

Published on by Cardiology and Cardiovascular Medicine

Innovative Research Award

Michael Keller
Virginia Commonwealth University, United States
Michael Keller
Affiliation Virginia Commonwealth University
Country United States
Scopus ID 59928747600
Documents 10
Citations 15
h-index 2
Subject Area Cardiac Surgery
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID
0009-0005-6104-0692

Michael Keller is a researcher affiliated with Virginia Commonwealth University whose academic contributions are focused on cardiac surgery, transplantation outcomes, thoracic surgery, and donor organ utilization. His scholarly work demonstrates an emphasis on clinical transplantation research, particularly within heart and lung transplantation, donor selection policies, and postoperative outcomes in cardiothoracic medicine. The researcher has contributed to multiple peer-reviewed publications indexed in Scopus and has participated in collaborative investigations addressing contemporary challenges in transplantation surgery and cardiovascular medicine.[1]

Abstract

The academic contributions of Michael Keller reflect ongoing research activity within the fields of cardiothoracic surgery and transplantation medicine. His publications address clinically significant topics including heart transplantation outcomes, donor organ utilization, lung allograft dysfunction, and transplantation policy assessment. The research profile demonstrates engagement with evidence-based clinical analysis and observational studies designed to improve understanding of transplantation practices and patient outcomes. Through collaborative multidisciplinary investigations, Keller has contributed to literature examining donor quality assessment, transplant eligibility, and post-transplant complications in cardiovascular medicine.[2]

Keywords

  • Cardiac Surgery
  • Heart Transplantation
  • Thoracic Surgery
  • Lung Transplantation
  • Donor Organ Utilization
  • Cardiovascular Medicine
  • Clinical Outcomes Research
  • Transplant Policy

Introduction

Cardiovascular and thoracic transplantation remain highly specialized areas of modern medicine requiring continual investigation into donor selection, postoperative management, and long-term patient outcomes. Researchers in this field contribute to improving clinical protocols and evidence-based transplantation strategies. Michael Keller has participated in scholarly studies that evaluate emerging transplantation policies and the utilization of donor organs in heart and lung transplantation settings.[3] The researcher’s work reflects interest in transplantation medicine within the broader context of cardiovascular surgery and thoracic clinical science. Several publications examine the outcomes associated with donor characteristics and recipient conditions, including hypoxemia, ventricular hypertrophy, diabetes mellitus, and donor circulatory status. These investigations contribute to ongoing discourse regarding transplantation optimization and clinical risk assessment.[4]

Research Profile

Michael Keller is affiliated with Virginia Commonwealth University and has established a developing scholarly profile in cardiac surgery and transplantation research. According to available Scopus indexing data, the researcher has accumulated 15 citations with an h-index of 2, reflecting measurable engagement within the academic literature.[1] The researcher’s publication portfolio includes collaborative investigations published in journals such as The Journal of Heart and Lung Transplantation, The Annals of Thoracic Surgery, Current Challenges in Thoracic Surgery, and Interdisciplinary CardioVascular and Thoracic Surgery. These studies primarily focus on transplant outcomes, donor organ evaluation, and thoracic surgical practices relevant to cardiovascular medicine.[5]

Research Contributions

Keller has contributed to research examining safety-net kidney transplantation after heart transplantation under updated clinical policies. This work evaluates early real-world outcomes associated with policy implementation and explores implications for transplant recipients and healthcare systems.[2] Additional investigations include the assessment of donor left ventricular hypertrophy in heart transplantation and the evaluation of outcomes using organs from hypoxemic donors in heart-lung transplantation. These studies address clinically significant concerns regarding donor suitability and postoperative outcomes in advanced transplantation medicine.[3] Research contributions also extend to lung transplantation outcomes from asphyxiation donors and the influence of preexisting diabetes mellitus on chronic lung allograft dysfunction. These analyses support broader understanding of risk factors and postoperative complications in thoracic transplantation practice.[4]

Publications

  1. Safety-net kidney transplantation after heart transplantation: Early real-world outcomes under the new policy. The Journal of Heart and Lung Transplantation (2026). DOI: 10.1016/j.healun.2026.01.033
  2. Contemporary Outcomes of Heart Transplantation with Moderate-to-Severe Donor Left Ventricular Hypertrophy. The Annals of Thoracic Surgery (2026). DOI: 10.1016/j.athoracsur.2026.03.047
  3. Outcomes and utilization of organs from hypoxemic donors in heart-lung transplantation: an observational study. Current Challenges in Thoracic Surgery (2026). DOI: 10.21037/ccts-2025-1-69
  4. Outcomes of lung transplantation from asphyxiation donors: reassessing hypoxic injury and implications for donation after circulatory death. Interdisciplinary CardioVascular and Thoracic Surgery (2026). DOI: 10.1093/icvts/ivag108
  5. The Impact of Preexisting Diabetes Mellitus on Chronic Lung Allograft Dysfunction After Lung Transplantation. Annals of Thoracic Surgery Short Reports (2026). DOI: 10.1016/j.atssr.2026.02.029

Research Impact

The research activity associated with Michael Keller contributes to contemporary discussions in transplantation surgery and cardiovascular medicine. Published investigations provide clinical insight into donor organ selection, transplantation policy evaluation, and post-transplant outcomes. Such studies support the advancement of evidence-informed decision-making within heart and lung transplantation programs.[5] The citation profile and indexed publications demonstrate emerging academic visibility within cardiothoracic surgical research. Collaborative authorship across multiple peer-reviewed journals indicates interdisciplinary engagement and participation in clinically relevant transplantation studies.[1]

Award Suitability

Michael Keller’s publication profile demonstrates suitability for recognition within the International Research Awards on Cardiology & Cardiovascular Medicine. The researcher’s contributions address clinically important themes in transplantation surgery and cardiovascular medicine, including donor evaluation, transplantation outcomes, and postoperative complications.[2] The combination of indexed publications, measurable citation activity, and participation in peer-reviewed cardiovascular research supports consideration for an innovative research distinction. The work reflects contemporary relevance to cardiac surgery and transplantation science while contributing to evidence-based clinical understanding.[3]

Conclusion

Michael Keller has contributed to the evolving field of cardiac and thoracic transplantation research through collaborative studies addressing donor selection, transplantation outcomes, and postoperative complications. The researcher’s scholarly profile demonstrates continued engagement in clinically relevant cardiovascular investigations published in peer-reviewed journals. These contributions support ongoing advancements in transplantation medicine and provide a foundation for future research within cardiothoracic surgery and cardiovascular healthcare.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Michael Keller, Author ID 59928747600. Scopus. https://www.scopus.com/authid/detail.uri?authorId=59928747600
  2. Kwon, Y. I. C., Ambrosio, M., Keller, M., et al. (2026). Safety-net kidney transplantation after heart transplantation: Early real-world outcomes under the new policy. The Journal of Heart and Lung Transplantation.
    DOI: https://doi.org/10.1016/j.healun.2026.01.033
  3. Kwon, Y. I. C., Ambrosio, M., Keller, M., et al. (2026). Contemporary Outcomes of Heart Transplantation with Moderate-to-Severe Donor Left Ventricular Hypertrophy. The Annals of Thoracic Surgery.
    DOI: https://doi.org/10.1016/j.athoracsur.2026.03.047
  4. Keller, M., Kwon, Y. I. C., Pei, J., et al. (2026). Outcomes and utilization of organs from hypoxemic donors in heart-lung transplantation: an observational study. Current Challenges in Thoracic Surgery.
    DOI: https://doi.org/10.21037/ccts-2025-1-69
  5. Kwon, Y. I. C., Ambrosio, M., Keller, M., et al. (2026). Outcomes of lung transplantation from asphyxiation donors: reassessing hypoxic injury and implications for donation after circulatory death. Interdisciplinary CardioVascular and Thoracic Surgery.
    DOI: https://doi.org/10.1093/icvts/ivag108